Homepage > Rare diseases > Search

Search for a rare disease

*
(*) mandatory field

Glutathione synthetase deficiency

Suggest an update
Your message has been sent Your message has not been sent. Please contact an administrator.
Disease definition

A rare disorder characterised by hemolytic anemia, associated with metabolic acidosis and 5-oxoprolinuria in moderate forms, and with progressive neurological symptoms and recurrent bacterial infections in the most severe forms.

ORPHA:32

Classification level: Disorder

Synonym(s):
  • Pyroglutamicaciduria

Prevalence: <1 / 1 000 000

Inheritance: Autosomal recessive

Age of onset: Neonatal

ICD-10: D55.1

ICD-11: 3A10.0Y

OMIM: 231900 266130

UMLS: C0398746

MeSH: C536835

GARD: 10047

MedDRA: 10079364

Summary
Epidemiology

This disease has been detected in at least 70 patients in more than 50 families worldwide.

Etiology

Several mutations have been identified in the gene encoding glutathione synthetase, localized to chromosome 20q11.2. Glutathione synthetase catalyses the last step in the synthesis of glutathione and a deficiency results in low levels of glutathione. Acidosis is due to reduced feedback inhibition of gamma-glutamyl cysteine synthetase in the gamma-glutamyl cycle, which ultimately leads to overproduction and accumulation of 5-oxoproline.

Diagnostic methods

The diagnosis usually involves the following: clinical findings, the finding of 5-oxoprolinuria, low levels of glutathione, low activity of glutathione synthetase, and mutation analysis of the glutathione synthetase gene.

Differential diagnosis

Other causes of 5-oxoprolinuria include 5-oxoprolinase deficiency, diet (certain infant formulas and tomato juice), severe burns, Stevens-Johnson syndrome, inborn errors of metabolism not involving the gamma-glutamyl cycle, e.g. X-linked ornithine trancarbamylase deficiency, urea cycle defects, tyrosinemia, as well as homocystinuria, drug metabolism (paracetamol, vigabatrin, flucloxacillin, netimicin), prematurity, malnutrition, pregnancy and nephropatic cystinosis.

Antenatal diagnosis

Antenatal diagnosis is possible.

Genetic counseling

Transmission is autosomal recessive.

Management and treatment

Management includes correction of the acidosis, supplementation with antioxidants and avoidance of drugs known to precipitate hemolytic crises in patients with glucose-6-phosphate dehydrogenase deficiency, e.g. phenobarbital, acetylsalicylic acid and sulfonamides.

Prognosis

A long-term follow up study of 28 patients with glutathione synthetase deficiency has showed that the factors most predictive of survival and long-term outcome are early diagnosis, correction of acidosis and early supplementation with vitamin C and vitamin E.

Last update: March 2007 - Expert reviewer(s): Dr Agne LARSSON - Dr Ellinor RISTOFF
A summary on this disease is available in Français, Español, Deutsch, Italiano, Português, Nederlands
Detailed information

Logo ERN: produced/endorsed by ERN(s) Logo FSMR: produced/endorsed by FSMR(s)

Guidelines
Emergency guidelines
Clinical practice guidelines
English (2017) - Haematologica Logo ERN
Disease review articles
Review article
English (2007) - Orphanet J Rare Dis
The documents contained in this website are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.